Tumarkin attacks are a feature of Ménière’s disease that generate a significant degree of disability. The surprising nature of these events is the main reason behind their associated morbidity. In this study we set out to evaluate auditory and vestibular function, as well as disability, in a population of patients who suffer Tumarkin attacks. We found that patients who suffer Tumarkin attacks are more disabled and experience severer and more frequent autonomic symptoms and that their hearing level is significantly worse in the asymptomatic ear, especially at low frequencies. Accordingly, we consider that treatment must be carefully planned to be as conservative as possible in terms of hearing and that psychiatric and/or psychological treatment must always be considered as an adjuvant therapy.

Keywords:
Vertigo, Disequilibrium, Posturography
1.
Black FO, Effron MZ, Burns DS: Diagnosis and management of drop attacks of vestibular origin: Tumarkin’s otolithic crisis. Otolaryngol Head Neck Surg 1982;90:256–262.
2.
Brantberg K, Ishiyama A, Baloh RW: Drop attacks secondary to superior canal dehiscence syndrome. Neurology 2005;64:2126–2128.
3.
Cohen H, Ewell LR, Jenkins HA: Disability in Ménière’s disease. Arch Otolaryngol Head Neck Surg 1995;121:29–33.
4.
Committee on Hearing and Equilibrium: Guidelines for diagnosing the evaluation of therapy in Ménière’s disease. Otolaryngol Head Neck Surg 1995;113:181–185.
5.
Goebel J: The ten-minute examination of the dizzy patient. Semin Neurol 2001;21:391–398.
6.
Horii A, Uno A, Kitahara T, Mitani K, Masumura C, Kizawa K, Kubo T: Effects of fluvoxamine on anxiety, depression, and subjective handicaps of chronic dizziness patients with or without neuro-otologic diseases. J Vestib Res 2007;17:1–8.
7.
Hwang JH, Ho HC, Hsu CJ, Yang WS, Liu TC: Diagnostic value of combining bilateral electrocochleography results for unilateral Ménière’s disease. Audiol Neurootol 2008;13:365–369.
8.
Ishiyama G, Ishiyama A, Baloh RW: Drop attacks and vertigo secondary to a non-Ménière otologic cause. Arch Neurol 2003;60:71–75.
9.
Jacobson GP, Newman CW: The development of the Dizziness Handicap Inventory. Arch Otolaryngol Head Neck Surg 1990;116:424–427.
10.
Kariya S, Cureoglu S, Fukushima H, Kusunoki T, Schachern PA, Nishizaki K, Paparella MM: Histopathologic changes of contralateral human temporal bone in unilateral Ménière’s disease. Otol Neurotol 2007;28:1063–1068.
11.
Kariya S, Cureoglu S, Fukushima H, Nomiya S, Nomiya R, Schachern PA, Nishizaki K, Paparella MM: Vascular findings in the stria vascularis of patients with unilateral or bilateral Ménière’s disease: a histopathologic temporal bone study. Otol Neurotol 2009;30:1006–1012.
12.
Kentala E, Havia M, Pyykkö I: Short-lasting drop attacks in Ménierè’s disease. Otolaryngol Head Neck Surg 2001;124:526–530.
13.
Kirby SE, Yardley L: Cognitions associated with anxiety in Ménière’s disease. J Psychosom Res 2009;66:111–118.
14.
Lee H, Yi HA, Lee SR, Ahn BH, Park BR: Drop attacks in elderly patients secondary to otologic causes with Ménière’s syndrome or non-Ménière peripheral vestibulopathy. J Neurol Sci 2005;232:71–76.
15.
Martin E, Perez N: Hearing loss after intratympanic gentamicin therapy for unilateral Ménière’s disease. Otol Neurotol 2003;24:800–806.
16.
Morales-Angulo C, Gallo-Terán J: Crisis otolíticas de Tumarkin o drop attacks en pacientes con enfermedad de Ménière. Acta Otorrinolaringol Esp 2005;56:469–471.
17.
Ozeki H, Iwasaki S, Murofushi T: Vestibular drop attack secondary to Ménière’s disease results from unstable otolithic function. Acta Otolaryngol 2008;128:887–891.
18.
Perez N, Garmendia I, García-Granero M, García-Tapia R: Factor analysis and correlation between Dizziness Handicap Inventory and Dizziness Characteristics and Impact on Quality of Life scales. Acta Otolaryngol Suppl 2001;545:145–154.
19.
Perez R, Chen JM, Nedzelski JM: The status of the contralateral ear in established unilateral Ménière’s disease. Laryngoscope 2004;114:1373–1376.
20.
Soto A, Labella T, Santos S, et al: The usefulness of computerized dynamic posturography for the study of equilibrium in patients with Ménière’s disease: correlation with clinical and audiological data. Hear Res 2004;196:26–32.
21.
Takumida M, Kakigi A, Takeda T, Anniko M: Ménière’s disease: a long-term follow-up study of bilateral hearing levels. Acta Otolaryngol 2006;126:921–925.
22.
Timmer FC, Zhou G, Guinan JJ, Kujawa SG, Herrmann BS, Rauch SD: Vestibular evoked myogenic potential (VEMP) in patients with Ménière’s disease with drop attacks. Laryngoscope 2006;116:776–779.
23.
Tumarkin A: The otolithic catastrophe: a new syndrome. BMJ 1936;2:175–177.
24.
van Cruijsen N, Jaspers JP, van de Wiel HB, Wit HP, Albers FW: Psychological assessment of patients with Ménière’s disease. Int J Audiol 2006;45:496–502.
25.
Wiltink J, Tschan R, Michal M, Subic-Wrana C, Eckhardt-Henn A, Dieterich M, Beutel ME: Dizziness: anxiety, health care utilization and health behavior – results from a representative German community survey. J Psychosom Res 2009;66:417–424.
26.
Yardley L, Masson E, Verschuur C, Haacke N, Luxon L: Symptoms, anxiety and handicap in dizzy patients: development of the Vertigo Symptoms Scale. J Psychosom Res 1992;36:731–741.
© 2010 S. Karger AG, Basel
2010
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.